Replies to post #42842 on OncoSec Medical Inc (ONCSQ)

[chickpea598]

Gargosky said the response in the two patients treated with Opdivo after ep-il12 was robust....so I would bet that Oncosec gets this into a fast track phase II trial same as PISCES....especially because the response rates in TNBC monotherapy are extremely low. This would probably get breakthrough status designation too.